Skip to Content

LBA: Lebrikizumab Provides Long-Term Efficacy and Safety in Atopic Dermatitis with a Well-Tolerated Safety Profile

Data presented by Prof. Dr. Diamant Thaçi, at EADV 2024 from the ADjoin long-term extension study show that lebrikizumab (LEB), an IL-13 inhibitor, maintains efficacy and safety over a 3-year period.

Get access

If you are a doctor or other health professional, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top